Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Zynlonta

- PMLiVE

Alnylam’s RNAi therapeutic recommended by NICE for hereditary form of amyloidosis

Amvuttra is given every three months, compared to every few weeks with existing therapies

- PMLiVE

Takeda’s all-oral multiple myeloma triplet therapy recommended by NICE

Ninlaro with lenalidomide and dexamethasone improved clinical outcomes

- PMLiVE

NICE recommends wider use of statins to cut risk of heart attack and stroke

The guidance comes after new evidence was considered on the side effects and safety of statins

- PMLiVE

Genentech and Kronos Bio announce oncology partnership worth over $570m

The companies aim to advance novel therapies for transcriptional targets in oncology

- PMLiVE

AbbVie and Immunome agree on multi-year oncology collaboration

The companies will identify up to ten antibody-target pairs using Immunome's discovery engine

- PMLiVE

Sanofi and Innate Pharma expand cancer therapeutics collaboration

The partnership is aimed at exploring the potential of natural killer cells therapeutics in oncology

- PMLiVE

ICR twin study indicates childhood leukaemia begins in the womb

The study, published in Leukemia, will help clinicians advise parents of twins with ALL

- PMLiVE

iOnctura awarded €17.5m from EIC Accelerator for novel pancreatic cancer therapy

The company dosed the first patient in a phase 1b study of IOA-289 earlier this month

- PMLiVE

Novartis receives EC approval for Pluvicto to treat adult cancer patients

Patients receiving Pluvicto plus best standard of care had a 38% reduction in the risk of death

- PMLiVE

Janssen’s Imbruvica shows promise in chronic lymphocytic leukaemia study

The data was shared during the 2022 American Society of Hematology Annual Meeting

- PMLiVE

Roche shares phase 3 Polivy data for previously untreated diffuse large B-cell lymphoma

Results continue to show significant reduction in risk of death for DLBCL patients

- PMLiVE

Pfizer shares updated pivotal phase 2 elranatamab data for multiple myeloma

There are 176,000 new cases of the disease worldwide for which there is currently no cure

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links